Commentary

Video

Mapping Progress in Pancreatic Cancer Surgery: Multidisciplinary Approach to Care

In this third episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, underscore the need for utilizing a multidisciplinary approach to determine the optimal care plan for each patient with pancreatic cancer.

In this third episode of OncChats: Mapping Progress Made in Pancreatic Cancer Surgery, Horacio J. Asbun, MD, and Domenech Asbun, MD, both of Baptist Health South Florida, underscore the need for utilizing a multidisciplinary approach to determine the optimal care plan for each patient with pancreatic cancer.

DA: The other aspect that I think has become much more the standard of care, which is something we interact with on a weekly basis here at Miami Cancer Institute, is the multidisciplinary approach to patients [with cancer]. Treatment decisions are no longer made by a single person on an island; they are made by a team of experts. Can you talk to how that has affected patient care?

HA: Yes. We’re surgeons, right? We think we should be the ones deciding everything. Traditionally, [the decision of whether] a patient was going to have surgery or not had been [made by] the surgeon, because if you were not capable of deciding, you were [considered to be] “weak;” that [was] the perception. All of that has gone out the window. If you’re working at a true multidisciplinary integrated care facility that’s [caring for] patients with pancreatic cancer or liver cancer, all those [cases] have to be prospectively presented on tumor boards. Basically, now you have a second or third or fourth or fifth opinion regarding what a patient [will need] to have done, and those opinions are given by different specialists.

Now, there are plenty of places that say, “Yeah, we present patient [cases on] tumor boards [and we use a] multidisciplinary approach” because those are the catchphrases. But the reality is, you definitely have to [do this.] When you joined us, [Domenech,] you came from finishing your fellowship at Mayo Clinic, where I had spent 10 years, as you know very well. At facilities like Mayo Clinic [and] Miami Cancer Institute, [these] things are real; it’s integrated care under one roof. Here, we enjoy the presence of people who are world renowned and who have helped us. This is not [an attempt] to advertise; I’m trying to say that there’s no justification today, unless there’s an access issue, [for treating] those patients in an isolated manner. You need to make the decisions of when to operate or not to operate and [whether they should receive] neoadjuvant [treatment] first, with a group of colleagues that you respect. In that way, you can [ensure that you] offer the best option for [each] patient.

With molecular studies, this is going to become much, much more important, and we have seen that [with regard to] the cysts, [for example]. We know now that aspirating the fluid of some of these cysts [may be beneficial;] in the past, we would just blindly observe [these patients]. Now, with the molecular analysis, we can detect with a much better sense whether those cysts may eventually become [cancerous] and [accordingly,] we [can] act on them a little earlier. As more mutations are discovered, it’s going to be more and more important to delegate that part of input into the decision-making process to other colleagues because we cannot do it all.

DA: Right, absolutely.

Check back on Wednesday for the next episode in this series.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on 5-year data for tremelimumab plus durvalumab in unresectable HCC.
Tanios Bekaii-Saab, MD, FACP
Michel Ducreux, MD, PhD, head, Gastrointestinal Oncology Unit, head, Gastrointestinal Oncology Tumor Board, Gustave Roussy; professor, oncology, Paris-Saclay University
Piotr Rutkowski, MD
Yelena Y. Janjigian, MD
Zhi Peng, MD